Eli Lilly’s weight-loss pill meets target in key diabetes trial
Results from US pharma group show oral drug reduced body weight by 10.5% on average
Related reading
Eli Lilly shot helped patients lose 29% of body weight
Trial results are a boost to US pharmaceutical company’s booming obesity business
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
The race to launch a pill for weight loss
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of…
Eli Lilly becomes first pharma group to join $1tn club
Shares have soared more than 40% this year over strong demand for weight-loss and diabetes drugs
New Novo Nordisk drug could beat market leaders for weight loss, early results…
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose